Cancer Treatment in The Abdomen
Traditional intravenous chemotherapy often fails to reach tiny cancer cells spread across the abdominal lining, limiting its ability to control advanced disease. To overcome this limitation, medical teams utilize a combined approach known as Cytoreductive Surgery with HIPEC to treat peritoneal surface malignancies.
The procedure pairs aggressive surgery with targeted heated chemotherapy. It transforms a historically palliative situation into an active intervention designed to eradicate visible disease and extend patient survival.
Surgical Removal and Heated Therapy
Cytoreductive Surgery, or CRS, involves removing all visible tumors from the abdominal cavity. Surgeons meticulously strip affected tissues to reduce the overall disease burden before administering any heated drugs.
Hyperthermic Intraperitoneal Chemotherapy, or HIPEC, follows immediately inside the operating room. Surgeons circulate chemotherapy heated to 42 to 43 degrees Celsius directly through the abdomen for 60 to 90 minutes, destroying microscopic cancer cells left behind by the scalpel.
Localized drug delivery uses heat to enhance penetration
Combining these two methods allows doctors to deliver concentrated treatment directly to the site of the disease without circulating it through the entire bloodstream. This localized delivery reduces systemic side effects while utilizing heat to dilate blood vessels and enhance drug penetration.
Elevated temperatures directly damage cancer cells and make them more permeable to the chemotherapy agents. Consequently, tissue absorption rates rise significantly compared to standard intravenous administration.
Peritoneal and Ovarian Malignancies
HIPEC is typically reserved for malignancies confined entirely to the abdominal cavity. These include peritoneal carcinomatosis originating from gastrointestinal sources such as colon or stomach cancer.
Specialists also apply the technique to advanced or recurrent ovarian cancer, appendiceal tumors involving pseudomyxoma peritonei, and rare peritoneal mesotheliomas. Candidates undergo thorough physical evaluations to determine if their specific disease profile matches the criteria for this intensive protocol.
The combined operation requires approximately six hours to complete under the care of specialized surgical teams. Patients receive the open CRS procedure first, immediately followed by the closed or open heated chemotherapy perfusion.
Recovery requires a hospital stay lasting between 7 and 14 days. Patients must undergo rigorous postoperative monitoring to manage healing and organ function.
Survival Rates and Reduced Recurrence
Integrating cytoreduction with heated chemotherapy offers several distinct advantages for patients facing peritoneal spread. The dual approach targets both macroscopic tumors and invisible micro-metastases to lower recurrence rates.
By confining high-dose chemotherapy to the peritoneal cavity, the treatment spares other organ systems from heavy toxicity. These clinical advantages combine to improve overall survival duration for carefully selected patient populations.
Abdominal Cancer Treatment Questions
What does CRS stand for and involve?
CRS stands for Cytoreductive Surgery, which is an extensive operation designed to remove all visible cancer nodules and affected tissues from inside the abdominal cavity.
Why must surgery and heated chemotherapy be combined?
Surgery alone frequently leaves behind microscopic cancer cells that can multiply and form new tumors. Introducing chemotherapy heated to 42 or 43 degrees Celsius directly into the abdomen allows the drugs to penetrate deep into remaining tissues where intravenous drugs cannot effectively reach.
How long is the hospital stay after the procedure?
Patients typically remain hospitalized for 7 to 14 days following the six-hour procedure to recover and monitor for potential postoperative complications.
Related reading